Kornimate/medical-research-clean huggingface dataset:
correlation between pulmonary rehabilitation and tfc

Conditions: COPD Received PR

Summary: to study the effects of lung rehabilitation on the heart's hemodynamic performance of patients with chronic bidirectional lung disease when performing routine and regular pr, and found that the effects of lung rehabilitation on the heart mechanism and patients long-term quality of life research.

this study will be conducted in the pulmonary rehabilitation treatment room on the 6th floor of the affiliated university hospital. the acceptance conditions are: (1) treatment of chronic pulmonary obstructive pulmonary disease in the lung rehabilitation clinic, and (2) signing of the subject's consent; exclusion conditions: (1) tracheostomized patients, (2) patients who cannot perform conventional lung rehabilitation, (3) patients who use respirators at home. the study is a prospective observational study. it is expected to include a total of 25 subjects. the study will be implemented for one year from the date of irb adoption. before performing pr treatment, performed the 6th and 12th every month, routine lung function, six-minute walking tests, and non-invasive cardiac output measurements are performed. the main results are: cardiac hemodynamic parameters.

Eligibility criteria:
inclusion criteria: * treatment of chronic pulmonary obstructive pulmonary disease in the lung rehabilitation clinic * signing of the subject's consent exclusion criteria: * gas-cut patients * patients who cannot perform conventional lung rehabilitation * patients who use respirators at home

Keywords: pulmonary rehabilitation negative pressure ventilation electrical cardiometry chronic obstructive pulmonary disease
spo2 hypoxia accuracy validation study

Conditions: Hypoxia

Summary: the primary objective of this study is to evaluate the % oxygen saturation by pulse oximetry accuracy of a combined pulse oximetry system which consists of a nonin sensor ), an adaptor cable, and an oximetry system during non-motion conditions.

the primary objective of this study is to evaluate the %spo2 accuracy of a combined pulse oximetry system which consists of a nonin sensor ), an adaptor cable, and an oximetry system during non-motion conditions.

Eligibility criteria:
inclusion criteria: * the subject is male or female * the subject is of any racial or ethnic group * the subject is ≥ 30 kg (≥ 66 pounds) in weight (self-reported) * the subject has at least one finger height of 0.2 - 1.0 inch (based on measurement) * the subject is between 18 years and 50 years of age (self-reported) * the subject shows no evidence of medical problems as indicated by satisfactory completion of the health assessment form * the subject has given written informed consent to participate in the study * the subject is both willing and able to comply with study procedures. exclusion criteria: * the subject has a bmi greater than 31 (based on weight and height) * the subject has had any relevant injury at the sensor location site (self-reported) * the subject has deformities or abnormalities that may prevent proper application of the device under test (based on examination) * the subject is current smoker (self-reported) * the subject has a known respiratory condition (self-reported) * the subject has a known heart or cardiovascular condition (self-reported) * the subject is currently pregnant, is actively trying to get pregnant, or who has a positive urine pregnancy test on the day of the study * the subject has a clotting disorder (self-reported) * the subject has raynaud's disease (self-reported) * the subject is known to have a hemoglobinopathy (self-reported) * the subject is on blood thinners or medication with aspirin (self-reported) * the subject has unacceptable collateral circulation from the ulnar artery (based on examination) * the subject is unwilling or unable to provide written informed consent to participate in the study * the subject is unwilling or unable to comply with the study procedures * the subject has another health condition which in the opinion of the principal investigator makes him/her unsuitable for testing.
safety and efficacy study of pregabalin in fibromyalgia

Conditions: Fibromyalgia

Summary: the purpose of this research study of pregabalin and fibromyalgia is to see if 1. pregabalin reduces the pain of fibromyalgia and if this effect lasts for six months and 2. to see if different dosages work better (reduce pain and mild to no side effects) for different people.


Eligibility criteria:
inclusion criteria: * at screening (v1), patients must meet the american college of rheumatology criteria for fibromyalgia (i.e. widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites * at screen (v1) and enrollment (v2), patients must have a score of greater than 40 mm on the pain visual analog scale exclusion criteria: * other severe pain or inflammatory muscle or rheumatologic disease other than fibromyalgia, active infections or untreated endocrine disorders; or severe depression and other serious hepatic, respiratory, hematologic or immunologic illness or active malignancy or history of malignancy (examples of prohibited diseases: hepatitis c, hiv, diabetes with nerve pain, other nerve pain (shingles), sleep apnea, epilepsy, narcolepsy, rheumatoid arthritis, generalized osteoarthritis, lupus, lyme disease unless sign and symptom free for 2 years, sjogren's syndrome, sarcoid, psoriatic arthritis, scleroderma) * previous participation in a clinical trial with pregabalin; currently receiving or pending disability claims or workmans compensation or civil litigation, or used other experimental medicines within 30 days of screening * creatinine clearance less than 60 ml/min (estimated from serum creatinine; low platelet and/or white blood cell counts; abnormal westergren erythrocyte sedimentation rate; abnormal antinuclear antibody (ana greater than 3u), or rheumatoid factor (rf greater than 80 iu/ml); abnormal (clinically relevant 12 lead ecg) * use of prohibited pain/sleep medications (including antidepressants, sedatives, hypnotics, nsaids, opiates, muscle relaxants) during the study. washout required prior to study entry.
t-cell brazil: prospective collection of data in t-cell lymphomas patients

Conditions: T-cell Lymphoma; NK-Cell Lymphoma; T-cell Lymphoma Adults

Summary: the designed study follows up on the previous one by the international t-cell project (bellei et al,, 2012) and its purpose is to verify whether a prospective collection of data would permit access to more accurate information permitting a better definition of prognosis and investigation of more adequate treatment strategies for these neoplasms. the analysis of patients distributed in all five macro regions of the country and a comparison among them will provide a real picture of the disease in brazil, limiting the bias probably found in the previous projects.

patients with diagnosis histologically confirmed t-cell or nk-cell lymphoma will be registered in the study, despite of their planned treatment. registration will be made on-line on a key restricted accessible web-database after obtaining the informed consent dated and signed by the patient. every registered patient has as well to undergo a central histopathology review by a panel of experts. the referring pathologist will collect and review the patological material sent by the participating centers, without knowing the clinical outcome of the patient. validated cases have to be supplied of information regarding treatment procedures and follow up updating for at least 5 years. the primary endpoint is the overall survival and other endpoints such as event free survival; progression free survival, complete and partial response rates.

Eligibility criteria:
inclusion criteria: * dated and signed informed consent; * t-cell or nk-cell diagnosis; * tissue biopsies adequate for diagnosis and classification and available for centralized review; * clinical, laboratory, image data available and registred in the website. exclusion criteria: -
validation of a seizure monitoring system

Conditions: Epilepsy

Summary: the investigators aim to determine the feasibility of using the medtronic linq device for epilepsy diagnosis, monitoring and management. the feasibility will be determined by comparing eeg signals from the linq system to the gold standard clinical recordings. if seizures can be identified using the linq device with the same level of accuracy as adjacent scalp eeg recording electrodes, then the linq will be deemed feasible.


Eligibility criteria:
inclusion criteria: * patients with epilepsy exclusion criteria: * women that are pregnant * patients that are highly dependant on medical care * patients that cannot give informed consent for themselves
efficacy and safety of patupilone in patients with advanced solid tumors in japan

Conditions: Tumors

Summary: the study will evaluate the safety and efficacy of patupilone in adult patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: * patients with a histologically/cytologically confirmed diagnosis of advanced solid tumors refractory to or unsuitable for standard therapy, or for whom no standard therapy exists * patients with who performance status of 0-1 ( karnofsky performance status of 80-100) * at least one measurable lesion exclusion criteria: * patients with any peripheral neuropathy * patients with unresolved diarrhea * patients with severe and/or uncontrolled medical conditions or infections that require systemic therapy other protocol-defined inclusion/exclusion criteria may apply

Keywords: advanced solid tumor patupilone
safely reduce cystoscopic evaluations for hematuria patients

Conditions: Hematuria; Urothelial Neoplasm; Urothelial Carcinoma; Bladder Cancer

Summary: the search-trial assess the clinical impact of a molecular urine test as a 'urine-first' strategy in the diagnostic workup of patients presenting with microscopic hematuria.

microscopic hematuria (mh) can be a sign of an underlying disease, including malignancy of the urinary tract, and is reason for referral to a urology clinic. the current standard diagnostic workup for mh patients includes visual inspection of the bladder by cystoscopy and upper tract imaging to rule out the presence of a tumor in the urinary tract. however, the a priori risk of cancer in patients with mh is only 2-5%. consequently, 95% of mh patients unnecessarily undergo invasive procedures, which are: i) uncomfortable and stressful for patients, ii) has a significant impact on limited available (financial) resources and iii) a ct scan is accompanied by exposure to ionizing radiation. previously we developed a molecular urine assay to detect urinary tract cancer in hematuria patients that had robust diagnostic performance; a negative predictive value \>99%, sensitivity, and specificity \>90%. the search-trial evaluates the clinical impact of a urine assay as a 'urine-first' strategy, meaning that only patients with an abnormal urine test results undergo invasive diagnostics. in this multicenter stepped-wedge cluster randomized trial we compare clinical outcomes by using a 'urine-first' strategy to 'care-as-usual', which is a cystoscopy and upper tract imaging in all patients presenting with mh. in addition, we assess patients' preferences, patients reported outcome measurements, and healthcare costs to show that a 'urine-first' strategy improves patients' quality of life and results in a more appropriate use of limited available resources.

Eligibility criteria:
inclusion criteria: * microscopically confirmed microscopic hematuria of voided urine defined as ≥3 erythrocytes per high power field * male patients ≥40 years * female patients ≥50 years exclusion criteria: * history of urothelial bladder- or urinary tract cancer * presence of macroscopic (visible) hematuria * woman who is or may be pregnant

Keywords: urinary biomarker hematuria urothelial carcinoma bladder cancer
the effectiveness of a physiotherapy technique in patients with chronic myofascial temporomandibular disorder

Conditions: Myofascial Pain Syndrome; Temporomandibular Disorder

Summary: participants with chronic orofacial pain caused by masticatory and neck muscles will be distributed in two groups, both followed with the same occlusal and self-care treatment. the experimental group will receive 5 sessions of physiotherapy applying a specific pressure on the trigger points while the control group will receive placebo through a simulation of the same technique. orofacial perceived pain, pain pressure thresholds, catastrophizing, kinesiophobia, cervical disability, depression and anxiety will be evaluated at baseline, immediately after treatment and 3 months later.


Eligibility criteria:
inclusion criteria: * patients ≥18 years. * patients diagnosed of myofascial tmd with at least one trp with referred pain. * tmd patients with a current complaint of myofascial pain with more than 6 months of evolution. * patients with myofascial tmd initially treated with splint currently used, that has not been modified in the last 6 months, without improvement. exclusion criteria: * patients treated with occlusal splint recently modified. * patients with acute tmj diseases. * patients with systemic disease, neurological and muscular diseases. * patients with psychiatric or psychological disorders. * patients with cervical disc hernia and acute whiplash injury. * changes in the painkillers intake during the experiment.

Keywords: chronic pain physical therapy modalities
the efficacy of lidocaine infusion in chronic unilateral migraine headache

Conditions: Chronic Migraine, Headache

Summary: study the efficacy of intravenous lidocaine infusion on patients with chronicunilateral migraine headache ..no of patients 80..willbe divided into 2 groups..first will receive medical treatment plus lidocaine infusion once weekly for 4 succesive weeks ,other will receive medical treatment plus saline infusion same regimne,follow up using monthly migraine days,vas score,midas score,quality of life questionaire,pre and post measurement of calcitonin gene related peptide

group a will receive medical treatment for migraine plus normal saline infusion,group b will receive medical treatment plus lidocaine infusion at dose from 3 to 4 mg per kg,computer generated random number will be used to identify the selected blocks and give the sequence of patients allocation,guarantee equal random in each group a set of permuted blocks will be generated. each block has 4 differently ordered treatment assignments.block 1 (aabb),block2(abab),block3(baba),block 4(abba),block5(baab),block 6(bbaa).

Eligibility criteria:
inclusion criteria: * age (18-55) years for both genders. * patients with chronic unilateral migraine headache for at least (3) month with vasscore more than (4). * patient who failed to respond to conservative treatment as medical treatment algorithm including at least tow preventive trials. excusion criteria: * patient with disabling chronic disease or psychiatric illness * unstable cardiac arrhythmia * patient refusal red flags
the ideal list session frequency protocol for cpps treatment

Conditions: Chronic Pelvic Pain Syndrome; Chronic Non-bacterial Prostatitis Type IIIB

Summary: the study will include 50 chronic pelvic pain syndrome (cpps) patients who will be randomised in 2 groups. group a (25 patients )will receive 6 list sessions with a frequency 1 session / week. group b (25 patients) will receive 6 list sessions with a frequency 2 sessions / week. national institutes of health chronic prostatitis symptom index(nhi-cpsi), international prostate symptom score (ipss), international index of erectile function (iief-ed) questionnaires will be answered before and at 1 and 3 month follow up visit. adverse events will be reported during the treatment and follow up period.


Eligibility criteria:
inclusion criteria: 1. participant must 18 to 60 years of age. 2. participant has signed and dated the appropriate informed consent document. 3. participant has had a clinical diagnosis of cp/cpps defined as symptoms of discomfort or pain in the perineal or pelvic region for at least a three (3) month period within the last six (6) months exclusion criteria: 1. participant has evidence of facultative gram negative or enterococcus with a value of ≥ 1000 cfu/ml in mid-stream urine (vb2). 2. participant has a history of prostate, bladder or urethral cancer. 3. participant has undergone pelvic radiation or systemic chemotherapy. 4. participant has undergone intravesical chemotherapy. 5. participant has unilateral orchialgia without pelvic symptoms, active urethral stricture or bladder stones, or any other urological condition associated with luts, any neurological disease or disorder affecting the bladder. 6. participant has undergone prostate surgery or treatment. 7. participant with penile or urinary sphincter implants. 8. participant has been diagnosed with cancer during the last 5 years, or had any surgery in the pelvis. 9. participant has a neurological impairment or psychiatric disorder preventing his understanding of consent and his ability to comply with the protocol. 10. psa\>3 and age \> 40 years 11. positive (suspicious for malignancy) digital rectal examination (dre).
safety, tolerability and pharmacokinetics of erx-963 in adults with myotonic dystrophy type 1

Conditions: Myotonic Dystrophy, Type 1 (DM1); Myotonic Dystrophy

Summary: participants in this study will receive two treatments, placebo and erx-963, on different days in a randomized fashion. the primary purpose of this study is to investigate the safety and tolerability of erx-963 in participants diagnosed with myotonic dystrophy, type 1 (dm1). the secondary purpose is to evaluate the potential of erx-963 treatment to reduce excessive daytime sleepiness / hypersomnia and improve cognitive function in dm1 participants compared to placebo treatment.

this study is evaluating single administration of two dose levels of erx-963 to explore the relationship between dose, safety, tolerability, exposure and clinical benefit. this is a multi-center, randomized, double-blind, placebo-controlled, two-treatment period crossover study in two cohorts of participants with dm1. participants who have consented and meet eligibility criteria will receive two treatments, placebo and erx-963, in a randomized crossover fashion with a washout period between the treatments. on treatment days, participants will receive treatment followed by repeated blood collection for pharmacokinetic analysis and administration of a battery of outcome measures relevant to sleep and cognition.

Eligibility criteria:
key inclusion criteria: * 18 to 65 years of age * dm1 defined by genetic testing or clinical-confirmation * epworth sleepiness scale (ess) of \> 11 or participants who have long sleep periods of an average of \> 10 hours a day * age of onset of dm1 greater than 16 years key exclusion criteria: * significant respiratory compromise * significant cardiac disease * diagnosis of symptomatic restless leg syndrome or significant untreated nocturnal hypoxias * significant moderate to severe hepatic insufficiency * clinically active depression, anxiety, or other medical condition that, in the investigator's opinion, would interfere with the safety and efficacy assessments * history of seizures * history of panic disorders

Keywords: excessive daytime sleepiness hypersomnia
efficacy and safety of nateglinide treatment in renal transplant recipients

Conditions: Renal Transplant Recipients; Posttransplant Diabetes Mellitus; Posttransplant Impaired Glucose Tolerance

Summary: the objective of the present study is to evaluate both the efficacy and safet of nateglinide in renal transplanta recipients with posttransplant diabetes mellitus or impaired glucose tolerance. primarily will the change in glucose tolerance and acute insuline responce be addressed.


Eligibility criteria:
inclusion criteria: * reduced glucose tolerance (fasting glucose \ 6.1 mmol/l or 2 hour glucose between \>= 10.0 mmol/l) * stable patients fgollowing renal transplantation, less than 25% variation in serum creatinine last week and serum creatinine \< 200 micromol/l exclusion criteria: * patients with indulin dependent diabetes mellitus before or after transplantation * planned change in daily prednisolone dose during the study period * haemoglobin \< 8g/dl

Keywords: nateglinide renal kidney transplantation diabets glucose
the effects of a systematic pain assessment approach on critically ill patients outcomes in icu

Conditions: Pain

Summary: the purpose of this study is to investigate the effectiveness of a systematic approach to pain assessment in the critically ill patients' outcome the investigators hypothesize that, patients who will undergo systematic pain assessment and they will have their results notified to physicians and nurses, will demonstrate favorable effects on pain intensity, more efficient use of sedatives and analgesics, duration of mechanical ventilation, length of icu stay, mortality, adverse events and complications, in relation to patients who will receive standard care alone. moreover it is expected that they will demonstrate altered levels of plasma neuropeptides and biochemical markers in peripheral blood.

appropriate pain management depends on the systematic and comprehensive assessment of pain. inaccurate pain assessment and the resulting inadequate treatment of pain in critically ill adults can have significant physiological and psychological consequences. the investigators will examine whether a systematic pain assessment approach can improve patients outcomes. 120 icu patients will be randomized either to control or intervention group. the control group will receive standard care plus pain assessments but nurses and physicians will be blind of these results. the intervention group will receive standard care plus systematic pain assessment and the results will be notified to nurses and physicians.

Eligibility criteria:
inclusion criteria: * 18 years and older * all patients with an estimated source of pain or due to immunological process as trauma, surgery, or due to general factors such as endotracheal intubation, interventional catheters exclusion criteria: * length of stay in the icu \<24 hours * the patient receives neuromuscular blockers, * the patient has a disease or condition, such as guillain-barre, peripheral neuropathy, which modifies sensory transmission of painful stimuli * the patient has a disease or condition which complicates the assessment of pain behavior, such as decerebration or vegetative state, agitation\> 3 in the richmond agitation sedation scale (rass)